6,6-二甲基双环[3.1.1]庚烷-2-甲醇 | 514-99-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 中文名称: 6,6-二甲基双环[3.1.1]庚烷-2-甲醇
• 英文名称: myrtanol
• 英文别名: trans-myrtanol；cis-myrtanol；(6,6-dimethyl-2-bicyclo[3.1.1]heptanyl)methanol
• CAS: 514-99-8
• 化学式: C₁₀H₁₈O
• mdl: MFCD03939168
• 分子量: 154.252
• InChiKey: LDWAIHWGMRVEFR-UHFFFAOYSA-N

物化性质

• 沸点：
  113-114 °C
• 密度：
  0.9859 g/cm3(Temp: 0 °C)
• LogP：
  2.759 (est)
• 保留指数：
  1240;1249;1258

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  6,6-二甲基双环[3.1.1]庚烷-2-甲醇 在 kieselguhr 、 镍 作用下， 160.0 ℃ 、5.88 MPa 条件下， 生成 6,6-二甲基双环[3.1.1]庚烷
  参考文献：
  名称：

  Study in Terpene Series. XI.¹ The Dehydroxymethylation of Bicyclic Primary Terpenic Alcohols by Hydrogenolysis in the Presence of Nickel Catalysts²

  摘要：

  DOI：

  10.1021/ja01153a014
• 作为产物：
  描述：

  beta-蒎烯 在 反式-双(三苯基膦)合氯化羰基铑(Ⅰ) lithium aluminium tetrahydride 、 盐酸羟胺 、 氢气 、 氧气 、 potassium carbonate 、 臭氧 、 三乙胺 作用下， 反应 106.0h， 生成 6,6-二甲基双环[3.1.1]庚烷-2-甲醇
  参考文献：
  名称：

  Azzena, Ugo; Chelucci, Giorgio; Delogu, Giovanna, Gazzetta Chimica Italiana, 1986, vol. 116, # 6, p. 307 - 316

  摘要：

  DOI：

文献信息

• [EN] (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS<br/>[FR] DÉRIVÉS DE (THIO)MORPHOLINE MODULATEURS DE S1P
  申请人：ABBOTT HEALTHCARE PRODUCTS BV

  公开号：WO2011023795A1

  公开（公告）日：2011-03-03

  The present invention relates to (thio)morpholine derivatives of the formula (I), wherein R1 is selected from cyano, (2-4C)alkynyl, (1-4C)alkyl, (3-6C)cycloalkyl, (4-6C)cycloalkenyl, (6-8C)bicycloalkyl, (8-10C)bicyclic group, each optionally substituted with (1-4C)alkyl, phenyl, biphenyl, naphthyl, each optionally substituted with one or more substituents independently selected from halogen, (1-4C)alkyloptionally substituted with one or more fluoro atoms, (2-4C)alkynyl, (1-4C)alkoxy optionally substituted with one or more fluoro atoms,amino, di(1-4C)alkylamino, -SO2-(1-4C)alkyl, -CO-(1-4C)alkyl, -CO-O-(1-4C)alkyl, -NH-CO-(1-4C)alkyl and (3-6C)cycloalkyl, phenyl substituted with phenoxy, benzyl, benzyloxy, phenylethyl or monocyclic heterocycle, each optionally substituted with (1-4C)alkyl, monocyclic heterocycle optionally substituted with halogen, (1-4C)alkyl or with phenyl optionally substituted with (1-4C)alkyl, and bicyclic heterocycle optionally substituted with (1-4C)alkyl; A is selected from -CO-O-, -O-CO-, -NH-CO-, -CO-NH, -C=C-, -CCH3-O- and the linking group –Y-(CH2)n-X- wherein Y is attached to R1 and selected from a bond, -O-, -S-, -SO-, -SO2-, -CH2-O-, -CO-, -O-CO-, -CO-O-, -CO-NH-, -NH-CO-, -C=C-and -C≡C-; n is an integer from 1 to 10; and X is attached to the phenylene / pyridyl group and selected from a bond, -O-, -S-, -SO-, -SO2 -, -NH, -CO-, -C=C-and -C≡C-; ring structure B optionally contains one nitrogen atom; R2 is H, (1-4C)alkyl optionally substituted with one or more fluoro atoms, (1-4C)alkoxy optionally substituted with one or more fluoro atoms, or halogen; and R3 is (1-4C)alkylene-R5 wherein the alkylene group may be substituted with (CH2)2 to form a cyclopropyl moiety or one or two halogen atoms, or R3 is is (3-6C)cycloalkylene-R5 or -CO-CH2-R5, wherein R5 is -OH, -PO3H2, -OPO3H2, -COOH, -COO(1-4C)alkyl or tetrazol-5-yl; R4 is H or (1-4C)alkyl; R6 is one or more substituents independently selected from H, (1-4C)alkyl or oxo; W is -O-, -S-, -SO- or -SO2-; or a pharmaceutically acceptable salt, a solvate or hydrate thereof; with the proviso that the derivative of formula (I) is not 2-(4-ethylphenyl)-4-morpholinoethanol or 4-[4-(2-hydroxyethyl)-2-morpholinyl]benzeneacetonitrile or a pharmaceutically acceptable salt, a solvate or hydrate thereof. The compounds of the invention have affinity to S1P receptors and may be used in the treatment, alleviation or prevention of S1P receptor mediated diseases and conditions.

  本发明涉及公式（I）的（硫）吗啉衍生物，其中R1从氰基，（2-4C）炔基，（1-4C）烷基，（3-6C）环烷基，（4-6C）环烯基，（6-8C）双环烷基，（8-10C）双环基团中选择，每个基团可选择地取代为（1-4C）烷基，苯基，联苯基，萘基，每个基团可选择地取代为一个或多个取代基，独立选择自卤素，（1-4C）烷基可选择地取代为一个或多个氟原子，（2-4C）炔基，（1-4C）氧烷基可选择地取代为一个或多个氟原子，氨基，二（1-4C）烷基氨基，-SO2-（1-4C）烷基，-CO-（1-4C）烷基，-CO-O-（1-4C）烷基，-NH-CO-（1-4C）烷基和（3-6C）环烷基，苯基取代为苯氧基，苄基，苄氧基，苯乙基或单环杂环烃，每个基团可选择地取代为（1-4C）烷基，单环杂环烃可选择地取代为卤素，（1-4C）烷基或取代为苯基的苯基，可选择地取代为（1-4C）烷基，和双环杂环烃可选择地取代为（1-4C）烷基；A从-CO-O-，-O-CO-，-NH-CO-，-CO-NH，-C=C-，-CCH3-O-和连接基-Y-（CH2）n-X-中选择，其中Y连接到R1并从键，-O-，-S-，-SO-，-SO2-，-CH2-O-，-CO-，-O-CO-，-CO-O-，-CO-NH-，-NH-CO-，-C=C-和-C≡C-中选择；n是1到10的整数；X连接到苯基/吡啶基团并从键，-O-，-S-，-SO-，-SO2-，-NH，-CO-，-C=C-和-C≡C-中选择；环结构B可选择地含有一个氮原子；R2是H，（1-4C）烷基可选择地取代为一个或多个氟原子，（1-4C）氧烷基可选择地取代为一个或多个氟原子，或卤素；R3是（1-4C）烷基-R5，其中烷基基团可取代为（CH2）2形成环丙基基团或一个或两个卤素原子，或R3是（3-6C）环烷基-R5或-CO-CH2-R5，其中R5是-OH，-PO3H2，-OPO3H2，-COOH，-COO（1-4C）烷基或四唑-5-基；R4是H或（1-4C）烷基；R6是一个或多个取代基，独立选择自H，（1-4C）烷基或氧代基；W是-O-，-S-，-SO-或-SO2-；或其药学上可接受的盐，溶剂或水合物；但是，公式（I）的衍生物不是2-（4-乙基苯基）-4-吗啉乙醇或4-[4-（2-羟乙基）-2-吗啉基]苯乙腈或其药学上可接受的盐，溶剂或水合物。本发明的化合物具有对S1P受体的亲和力，可用于治疗、缓解或预防S1P受体介导的疾病和症状。
• Base-mediated cascade amidination/<i>N</i>-alkylation of amines by alcohols
  作者：Chunyan Zhang、Zuyu Liang、Fenghong Lu、Xiaofei Jia、Guoying Zhang、Mao-Lin Hu

  DOI：10.1039/d0cc04831c

  日期：——

  amidination/N-alkylation reaction of amines by alcohols has been developed. For the first time, nitriles have been identified as an efficient and benign water acceptor reagent in N-alkylation. Notably, the procedure tolerates a series of functional groups, such as methoxyl, halo, vinyl and hetero groups, providing a convenient method to construct different substituted diamino compounds, 15N labeled

  已经开发了碱通过醇介导的胺的级联酰胺化/ N-烷基化反应。首次在N-烷基化中将腈鉴定为有效且良性的水受体试剂。值得注意的是，该方法可耐受一系列官能团，例如甲氧基，卤素，乙烯基和杂基，为构建不同的取代的二氨基化合物，15 N标记的胺提供了便利的方法，并且可以按比例放大至1 mol规模，可提供138.7 g一锅即可获得高收率的所需产品。机理研究为t -BuOK促进胺与腈酰胺化提供了有力的证据。
• 2-Bromo-3,4,4-trichlorobut-3-enoates of certain natural alcohols, phenols, and oximes of carbonyl compounds
  作者：E. A. Dikusar、V. I. Potkin、N. G. Kozlov、S. K. Petkevich、N. V. Kovganko

  DOI：10.1007/s10600-006-0093-7

  日期：2006.5

  Previously undescribed 2-bromo-3,4,4-trichlorobut-3-enoates 1b-23b were synthesized in 84–91% yield from natural alcohols including terpenes and steroids, plant phenols, and oximes of natural carbonyl compounds 1a-23a by reaction of 2-bromo-3,4,4-trichlorobut-3-enoyl chloride in the presence of pyridine.

  先前未见报道的2-溴-3,4,4-三氯-3-丁烯酸酯1b-23b，通过2-溴-3,4,4-三氯-3-丁烯酰氯在吡啶存在下的反应，以84-91%的产率从天然醇（包括萜类和甾体、植物酚类以及天然羰基化合物的肟1a-23a）中合成。
• Compounds, Compositions and methods for insect control
  申请人：DeLong Anthony Mitchell

  公开号：US20050025795A1

  公开（公告）日：2005-02-03

  Rapidly acting compositions having vapor phase insecticidal activity comprise natural products or natural product-based materials. Further, these materials are non-petroleum based, are typically 100% biodegradable, and typically do not persist in the environment, unlike traditional pesticides. The compositions kill susceptible insects on contact in seconds, even the notoriously hardy peripleneta species. The compositions also kill insects behind cracks and crevices and when sprayed onto absorbent surfaces such as wood and plasterboard, where traditional contact insecticides work poorly or not at all. New methods of testing insecticides can be used to quantify these effects.

  快速作用的具有蒸汽相杀虫活性的组合物包括天然产品或基于天然产品的材料。此外，这些材料不基于石油，通常是100%可生物降解的，并且通常不会在环境中残留，不像传统杀虫剂。这些组合物能在接触时在几秒钟内杀死易感昆虫，甚至是以硬质蟑螂物种而著称的物种。这些组合物还能在裂缝和缝隙后杀死昆虫，并且当喷洒到吸收性表面（如木材和石膏板）时，传统的接触杀虫剂效果不佳或根本不起作用。可以使用新的杀虫剂测试方法来量化这些效果。
• Hydronopol derivatives as agonists on human ORL1 receptors
  申请人：Mentzel Matthias

  公开号：US20050131004A1

  公开（公告）日：2005-06-16

  The invention relates to a group of hydronopol derivatives which are agonists on human ORL1 (nociceptin) receptors. The invention also relates to the preparation of these compounds, to pharmaceutical compositions containing a pharmacologically active amount of at least one of these novel hydronopol derivatives as an active ingredient, as well as to the use of these pharmaceutical compositions for the treatment of disorders in which ORL1 receptors are involved. The invention relates to compounds of the general formula (1) wherein the symbols have the meanings as given in the description.

  本发明涉及一组氢诺普尔衍生物，它们是人ORL1（痛敏素）受体的激动剂。本发明还涉及这些化合物的制备方法，以及含有至少一种这些新型氢诺普尔衍生物作为活性成分的药理活性量的药物组合物，以及这些药物组合物用于治疗涉及ORL1受体的疾病的使用。本发明涉及通式（1）的化合物，其中符号的含义如说明书中所述。